The Sprint to Develop Coronavirus Antivirals
The preclinical work leading to the discovery of PF-07321332 (nirmatrelvir) is described in the Featured Article summarized in this Viewpoint. This work resulted in an Emergency Use Authorization (EUA) for Paxlovid within two years of the project's start. In addition to the medicinal chemistry approach taken, the authors describe how they achieved this remarkable speed.
Authors
- Michael F. T. Koehler (ORCID: https://orcid.org/0000-0003-0967-8304)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c00578
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00